Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.89
0.181.54%
al cierre: -
$11.68
-0.21-1.76%
After hour: Aug 15, 7:30 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Cogent Biosciences Inc ha un obiettivo di prezzo di consenso pari a $20, stabilito in base alle ultime valutazioni degli analisti di 13. Le ultime 3 valutazioni degli analisti sono state rilasciate da JP Morgan, HC Wainwright & Co. y Citigroup il agosto 7, 2025, agosto 6, 2025 y julio 18, 2025. Con un obiettivo di prezzo medio di $24.33 tra le JP Morgan, HC Wainwright & Co. y Citigroup, c'è un implicito 108.32% upside per Cogent Biosciences Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
JP Morgan
HC Wainwright & Co.
Citigroup
Guggenheim
Baird
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Cogent Biosciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/07/2025 | 156.84% | JP Morgan | $29 → $30 | Maintains | Overweight | |||
08/06/2025 | 79.79% | HC Wainwright & Co. | $22 → $21 | Maintains | Buy | |||
07/18/2025 | 88.35% | Citigroup | $15 → $22 | Maintains | Buy | |||
07/10/2025 | 148.27% | JP Morgan | $25 → $29 | Maintains | Overweight | |||
07/08/2025 | 88.35% | HC Wainwright & Co. | $12 → $22 | Maintains | Buy | |||
07/08/2025 | 45.54% | Guggenheim | $17 → $17 | Reiterates | Buy → Buy | |||
07/08/2025 | -22.95% | Baird | $7 → $9 | Maintains | Neutral | |||
07/07/2025 | 139.71% | Jefferies | $23 → $28 | Maintains | Buy | |||
07/07/2025 | 54.1% | Leerink Partners | $16 → $18 | Maintains | Outperform | |||
06/17/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
05/29/2025 | 114.03% | JP Morgan | $21 → $25 | Maintains | Overweight | |||
05/20/2025 | 2.73% | HC Wainwright & Co. | $14 → $12 | Maintains | Buy | |||
05/07/2025 | -40.07% | Baird | $8 → $7 | Maintains | Neutral | |||
03/07/2025 | 45.54% | Scotiabank | → $17 | Initiates | → Sector Outperform | |||
02/27/2025 | -31.51% | Baird | $10 → $8 | Maintains | Neutral | |||
02/26/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
01/14/2025 | 19.86% | HC Wainwright & Co. | $17 → $14 | Maintains | Buy | |||
12/11/2024 | 28.42% | Needham | $15 → $15 | Downgrade | Buy → Hold | |||
12/11/2024 | — | HC Wainwright & Co. | — | Reiterates | Buy → Buy | |||
12/10/2024 | 28.42% | Needham | $15 → $15 | Reiterates | Buy → Buy | |||
12/09/2024 | 28.42% | Needham | $15 → $15 | Reiterates | Buy → Buy | |||
11/14/2024 | 79.79% | JP Morgan | $19 → $21 | Maintains | Overweight | |||
11/13/2024 | 28.42% | Needham | $16 → $15 | Maintains | Buy | |||
11/04/2024 | 45.54% | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
10/24/2024 | 36.98% | Needham | $16 → $16 | Reiterates | Buy → Buy | |||
09/24/2024 | 28.42% | Citigroup | $13 → $15 | Maintains | Buy | |||
09/05/2024 | -14.39% | Baird | $8 → $10 | Maintains | Neutral | |||
09/03/2024 | 45.54% | HC Wainwright & Co. | $19 → $17 | Maintains | Buy | |||
08/07/2024 | 62.66% | JP Morgan | $22 → $19 | Maintains | Overweight | |||
08/07/2024 | 54.1% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
06/27/2024 | 54.1% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
06/17/2024 | 62.66% | HC Wainwright & Co. | $19 → $19 | Reiterates | Buy → Buy | |||
06/17/2024 | 54.1% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
05/24/2024 | -14.39% | Wedbush | $10 → $10 | Reiterates | Neutral → Neutral | |||
05/13/2024 | 62.66% | HC Wainwright & Co. | $19 → $19 | Reiterates | Buy → Buy | |||
05/08/2024 | 54.1% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
02/27/2024 | 71.22% | JP Morgan | $18 → $20 | Maintains | Overweight | |||
02/26/2024 | 54.1% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
02/26/2024 | 11.3% | Citigroup | $11 → $13 | Maintains | Buy | |||
02/26/2024 | -31.51% | Baird | $14 → $8 | Downgrade | Outperform → Neutral | |||
02/23/2024 | -14.39% | Wedbush | $5 → $10 | Maintains | Neutral | |||
02/12/2024 | 28.42% | Needham | $15 → $15 | Reiterates | Buy → Buy | |||
02/08/2024 | -5.83% | Citigroup | → $11 | Initiates | → Buy | |||
12/15/2023 | 11.3% | HC Wainwright & Co. | $27 → $13 | Maintains | Buy | |||
12/11/2023 | -57.19% | Wedbush | $20 → $5 | Downgrade | Outperform → Neutral | |||
12/08/2023 | 54.1% | JP Morgan | → $18 | Initiates | → Overweight | |||
12/05/2023 | 88.35% | Needham | $22 → $22 | Reiterates | Buy → Buy | |||
11/27/2023 | 88.35% | Needham | → $22 | Reiterates | Buy → Buy | |||
09/19/2023 | 88.35% | Needham | → $22 | Reiterates | Buy → Buy | |||
09/05/2023 | 88.35% | Needham | → $22 | Reiterates | Buy → Buy | |||
08/30/2023 | 131.15% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy | |||
08/09/2023 | 88.35% | Needham | → $22 | Reiterates | Buy → Buy | |||
06/13/2023 | 122.59% | Guggenheim | → $26 | Reiterates | Buy → Buy | |||
06/12/2023 | 88.35% | Piper Sandler | → $22 | Maintains | Overweight | |||
06/08/2023 | 131.15% | HC Wainwright & Co. | $28 → $27 | Maintains | Buy | |||
06/05/2023 | 79.79% | Needham | → $21 | Reiterates | Buy → Buy | |||
05/11/2023 | 79.79% | Needham | → $21 | Reiterates | Buy → Buy | |||
04/28/2023 | 71.22% | Baird | → $20 | Initiates | → Outperform | |||
04/19/2023 | 96.91% | Needham | → $23 | Maintains | Buy | |||
03/27/2023 | 139.71% | HC Wainwright & Co. | → $28 | Assumes | → Buy | |||
03/15/2023 | 122.59% | Guggenheim | → $26 | Reiterates | → Buy | |||
03/15/2023 | 96.91% | Needham | $24 → $23 | Maintains | Buy | |||
01/05/2023 | 71.22% | SVB Leerink | $18 → $20 | Maintains | Outperform | |||
12/14/2022 | 105.47% | Needham | → $24 | Initiates | → Buy | |||
12/13/2022 | 105.47% | Guggenheim | $22 → $24 | Maintains | Buy | |||
11/17/2022 | 54.1% | SVB Leerink | $20 → $18 | Maintains | Outperform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Cogent Biosciences (COGT)?
El último precio objetivo de Cogent Biosciences (NASDAQ:COGT) fue comunicado por JP Morgan el agosto 7, 2025. La firma de analistas fijó un precio objetivo para $30.00 que espera COGT a rise dentro de 12 meses (un posible 156.84% upside). 28 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Cogent Biosciences (COGT)?
La última calificación de analistas para Cogent Biosciences (NASDAQ:COGT) fue proporcionada por JP Morgan, y Cogent Biosciences mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Cogent Biosciences (COGT)?
No hay última actualización para Cogent Biosciences
¿Cuándo fue la última revisión a la baja de Cogent Biosciences (COGT)?
La última revisión a la baja de Cogent Biosciences Inc se produjo en diciembre 11, 2024, cuando Needham cambió su precio objetivo de $15 a $15 para Cogent Biosciences Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Cogent Biosciences (COGT)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Cogent Biosciences, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Cogent Biosciences se registró el agosto 7, 2025, por lo que la próxima calificación estará disponible en torno al agosto 7, 2026.
¿Es correcta la calificación de los analistas sobre Cogent Biosciences (COGT)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Cogent Biosciences (COGT) fue un mantuvo con un precio objetivo de $29.00 a $30.00. El precio actual al que cotiza Cogent Biosciences (COGT) es de $11.68, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.